Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH)
Archive ouverte
Carrieri, Maria Patrizia | Serfaty, Lawrence | Vilotitch, Antoine | Poizot-Martin, Isabelle | Loko, Marc-Arthur | Lions, Caroline | Salmon-Ceron, Dominique | Spire, Bruno | Dabis, François | Salmon, D | Dabis, F | Winnock, M | Sogni, P | Benhamou, Y | Trimoulet, P | Izopet, J | Paradis, V | Spire, B | Carrieri, P | Katlama, C | Pialoux, G | Valantin, M A | Bonnard, P | Rosenthal, E | Garipuy, D | Bouchaud, O | Gervais, A | Lascoux-Combe, C | Goujard, C | Lacombe, K | Duvivier, C | Vittecoq, D | Neau, D | Morlat, P | Banisadr, F | Meyer, L | Boufassa, F | Dominguez, S | Autran, B | Roque, a M | Solas, C | Fontaine, H | Serfaty, L | Chêne, G | Costagliola, D | Zucman, D | Simon, A | Billaud, E | Miailhes, P | Devoto, J Polo | Couffin-Cadiergues, S | Mehawej, H | Makhlouf, Z | Dubost, G | Tessier, F | Gibault, L | Beuvon, F | Chambon, E | Lazure, T | Krivine, A | Charlotte, F | Fourati, S | Cacoub, P | Nafissa, S | Zaegel, O | Ménard, A | Geneau, P | Tamalet, C | Bani-Sadr, F | Slama, L | Lyavanc, T | Callard, P | Bendjaballah, F | Le-Pendeven, C | Marchou, B | Alric, Laurent | Barange, K | Metivier, S | Fooladi, A | Selves, J | Nicot, F | Durant, J | Haudebourg, J | Saint-Paul, M C | Ziol, M | Baazia, Y | Uzan, M | Bicart-See, A | Ferro-Collados, M J | Yéni, P | Adle-Biassette, H | Molina, J M | Combe, C Lascoux | Bertheau, P | Duclos, J | Palmer, P | Girard, P M | Campa, P | Wendum, D | Cervera, P | Adam, J | Harchi, N | Delfraissy, J F | Quertainmont, Y | Pallier, C | Lortholary, O | Shoai-Tehrani, M | Lacaze-Buzy, L | Caldato, S | Bioulac-Sage, P | Reigadas, S | Majerholc, C | Guitard, F | Boue, F | Kansau, I | Chambrin, V | Pignon, C | Berroukeche, L | Fior, R | Martinez, V | Deback, C | Lévy, Y | Lelièvre, J D | Lascaux, a S | Melica, G | Raffi, F | Alavena, C | Rodallec, A | Peyramond, D | Chidiac, C | Ader, F | Biron, F | Boibieux, A | Cotte, L | Ferry, T | Perpoint, T | Koffi, J | Zoulim, F | Bailly, F | Lack, P | Radenne, S | Amiri, M | Beniken, D | Ritleng, a S | Azar, M | Honoré, P | Breau, S | Joulie, A | Mole, M | Bolliot, C | Chouraqui, F | Touam, F | André, F | Ouabdesselam, N | Partouche, C | Alexandre, G | Ganon, A | Champetier, A | Hue, H | Brosseau, D | Brochier, C | Thoirain, V | Rannou, M | Bornarel, D | Gillet, S | Delaune, J | Pambrun, E | Dequae-Merchadou, L | Frosch, A | Maradan, G | Cheminat, O | Marcellin, F | Mora, M | Protopopescu, C
Edité par
CCSD ; Oxford University Press (OUP) -
International audience.
Diabetes and insulin resistance (IR) is common in human immunodeficiency virus-hepatitis C virus (HIV-HCV)-coinfected patients, a population also concerned with elevated cannabis use. Cannabis has been associated with reduced IR risk in some population-based surveys. We determined whether cannabis use was consistently associated with reduced IR risk in HEPAVIH, a French nationwide cohort of HIV-HCV-coinfected patients.Methods: HEPAVIH medical and sociobehavioral data were collected (using annual self-administered questionnaires). We used 60 months of follow-up data for patients with at least 1 medical visit where IR (using homeostatic model assessment of insulin resistance [HOMA-IR]) and cannabis use were assessed. A mixed logistic regression model was used to evaluate the association between IR risk (HOMA-IR > 2.77) and cannabis use (occasional, regular, daily).Results: Among the 703 patients included in the study (1287 visits), 323 (46%) had HOMA-IR > 2.77 for at least 1 follow-up visit and 319 (45%) reported cannabis use in the 6 months before the first available visit. Cannabis users (irrespective of frequency) were less likely to have HOMA-IR > 2.77 (odds ratio [95% confidence interval], 0.4 [.2-.5]) after adjustment for known correlates/confounders. Two sensitivity analyses with HOMA-IR values as a continuous variable and a cutoff value of 3.8 confirmed the association between reduced IR risk and cannabis use.Conclusions: Cannabis use is associated with a lower IR risk in HIV-HCV-coinfected patients. The benefits of cannabis-based pharmacotherapies for patients concerned with increased risk of IR and diabetes need to be evaluated in clinical research and practice.
